Weight Loss

The category in 2026

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Weight-loss peptide therapy is dominated by GLP-1 receptor agonists. The category has matured rapidly: in 2025 the conversation was "is semaglutide better than tirzepatide?" In 2026 it's "is the new triple-agonist Retatrutide worth waiting for, and what happens when the FDA's May 4 proposal forces compounded GLP-1s off the market?" The answers matter financially — branded GLP-1 list prices run $1,000–1,400 per month and insurance coverage remains uneven.

Three things distinguish 2026 from prior years. First, head-to-head clinical data now exists: SURMOUNT-5 directly compared tirzepatide to semaglutide for obesity at 72 weeks, settling the dual-vs-single-agonist question (tirzepatide produced 20.2% mean weight loss vs 13.7% for semaglutide). Second, non-injectable formulations are real: oral semaglutide (Rybelsus) is FDA-approved, oral non-peptide GLP-1 (orforglipron) is in late-stage Phase 3, and the daily-pill obesity dosing is being formally evaluated. Third, the regulatory landscape is in flux: the May 4, 2026 FDA proposal to exclude semaglutide and tirzepatide from the 503B Outsourcing Facility bulks list materially affects how compounded GLP-1s reach patients.

The four molecules that matter

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Semaglutide (Wegovy / Ozempic / Rybelsus). Single-target GLP-1 receptor agonist. The most-prescribed obesity medication in 2026. Strongest cardiovascular outcomes data in the class — the SELECT trial showed a 20% reduction in major adverse cardiovascular events. Mean weight loss at 68 weeks: 14.9% (STEP-1). Once-weekly subcutaneous injection (Wegovy 1.0–2.4 mg weekly maintenance). Read the semaglutide fact box →

Tirzepatide (Zepbound / Mounjaro). Dual GLP-1 + GIP receptor agonist. Mean weight loss at 88 weeks: 22.5% (SURMOUNT-4). The only GLP-1-class drug with an FDA indication for obstructive sleep apnea (Zepbound, Dec 2024). Once-weekly subcutaneous injection. Tirzepatide fact box →

Retatrutide (investigational). Triple agonist of GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH-1 readout: ~24% mean total body weight reduction at 48 weeks — the highest yet documented for a single weight-loss molecule. The glucagon component drives additional energy expenditure and may avoid the metabolic slowdown observed with GLP-1 monotherapy. Eli Lilly has not yet filed for FDA approval. Expected filing H2 2026; possible approval 2027. Retatrutide details →

Orforglipron (investigational). Eli Lilly's first non-peptide oral GLP-1 receptor agonist. Small-molecule structure means no SNAC carrier required, no food-timing restrictions, and no injection. Phase 3 ATTAIN-1 read out April 2026 with ~14.7% mean weight loss at 72 weeks. PDUFA date pending. The "Wegovy in pill form without the fasting protocol" use case. Orforglipron details →

The CagriSema wildcard

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Novo Nordisk's CagriSema — a fixed-dose combination of cagrilintide (long-acting amylin analog) plus semaglutide — read out REDEFINE 1 in March 2026 with ~22.7% mean weight loss vs ~16.1% for semaglutide alone over 68 weeks. Filed with the FDA Q1 2026; PDUFA expected late 2026. CagriSema gives Novo a credible answer to tirzepatide and (potentially) retatrutide, and the combination format may extend the GLP-1 franchise as Wegovy patents face their first competitive pressure.

The non-injectable pathways

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Injection is still the gold-standard route for GLP-1s — bioavailability is ~80% versus ~1% for oral semaglutide. But three non-injectable options are real in 2026:

Oral semaglutide (Rybelsus) uses a SNAC absorption-enhancer carrier to push oral bioavailability from <0.1% to ~1%. The protocol is demanding (fasted, ≤4oz water, no food/drink for 30 min after) and real-world weight loss runs 4–8% — about half of injectable. Worth it for needle-aversion or strong pill preference; not equivalent efficacy. Read the oral-vs-injectable comparison →

Orforglipron sidesteps the bioavailability problem by being a small molecule, not a peptide. No SNAC carrier needed; no food-timing restrictions. Phase 3 efficacy is roughly equivalent to current-generation injectable GLP-1s. The pill-form GLP-1 the market has been waiting for.

Tesofensine is a non-GLP-1 oral pill (triple monoamine reuptake inhibitor) approved in Mexico for weight loss, with FDA application stalled over cardiovascular safety. Not in the same evidence tier as GLP-1s but covered for completeness. Tesofensine details →

The compounding situation as of May 2026

Evidence tier: 5 — editorial framing of the peptide-page entity context.

The May 4, 2026 FDA proposal would exclude semaglutide and tirzepatide from the 503B Outsourcing Facility bulks list. If finalized after the public comment period (closes August 3, 2026), large-scale compounding of these two GLP-1s ends. Patient-specific 503A compounding under documented medical necessity continues to be permitted. Brand-name Wegovy and Zepbound are unaffected.

The full explainer covering all four patient pathways — switch to brand, find a 503A pharmacy, taper to maintenance, or wait — is in the 503B compounding cliff article.

Muscle-sparing and maintenance adjuncts

Evidence tier: 5 — editorial framing of the peptide-page entity context.

The standard concern with GLP-1 weight loss is loss of lean mass alongside fat loss. Two peptide adjuncts are increasingly stacked:

Tesamorelin — FDA-approved (as Egrifta) for HIV-associated visceral fat reduction. Off-label use as a "muscle-sparing" GLP-1 adjunct because endogenous GH/IGF-1 elevation supports lean mass retention.

AOD-9604 — Modified C-terminal fragment of human growth hormone. Promoted as a fat-loss peptide that doesn't elevate IGF-1. Multiple Phase 2b trials failed to show meaningful weight loss vs placebo as monotherapy; positioned as an adjunct rather than a replacement.

Neither is FDA-approved for the muscle-sparing GLP-1-stack indication. Both remain off-label and require physician supervision.

What we cover under this pillar

Evidence tier: 5 — editorial framing of the peptide-page entity context.

• Direct comparisons: Semaglutide vs Tirzepatide, Retatrutide vs Tirzepatide, Oral vs Injectable Semaglutide
• Regulatory: 503B compounding cliff explainer, PCAC July 2026 tracker
• Non-injectable formats: All non-injectable GLP-1 options
• Find a clinic: Telehealth GLP-1 providers, all 50 states

Open questions we are tracking

Evidence tier: 5 — editorial framing of the peptide-page entity context.

• Will the FDA finalize the 503B exclusion in 2026, or will the comment period push final-rule timing into 2027?
• Will Retatrutide's filing arrive in H2 2026 as currently expected, and will the cardiovascular outcomes program be sufficient for a clean approval?
• Does Orforglipron's bioavailability advantage translate into dropping the dose-response ceiling that's limited oral semaglutide?
• Will any 503A pathway emerge that delivers meaningful compounded supply post-503B exclusion, or does the entire compounded GLP-1 market collapse?

We update this page as each of these resolves.

Who should use this pillar

Evidence tier: 5 — editorial framing of the peptide-page entity context.

> Evidence tier: 5 — editorial framing of pillar-page audience scope; no clinical evidence claim made.

This pillar is written for four reader audiences with overlapping but distinct decision-making needs. First, adults with a BMI ≥30 (or ≥27 with at least one weight-related comorbidity) who meet the FDA-label criteria for branded GLP-1 therapy and are evaluating Semaglutide versus Tirzepatide as their starting point. Second, patients with type 2 diabetes weighing GLP-1 selection on the combined axis of glycemic control plus weight loss — the SURPASS program data is more relevant here than SURMOUNT. Third, patients with established cardiovascular disease for whom the SELECT trial's 20% MACE reduction with semaglutide changes the risk-benefit framing meaningfully. Fourth, patients facing the 2026 compounding cliff who currently access compounded GLP-1s and need to plan a transition path before the May 4 FDA proposal finalizes — the practical reader question here is operational, not clinical.

We do not write for adolescent or pediatric populations (a separate evidence base applies). We do not write for users seeking "performance" or recreational weight loss outside FDA-label indications — that audience is served elsewhere, and the YMYL framing of this platform pushes us toward the medically-indicated reader. Patients with a history of medullary thyroid carcinoma, MEN2, severe gastroparesis, or active pancreatitis fall outside the GLP-1 candidate pool entirely. The 503B compounding cliff article maps the transition pathways in detail.

Decision framework — choosing between molecules in this category

Evidence tier: 5 — editorial framing of the peptide-page entity context.

> Evidence tier: 5 — editorial decision-framework synthesis from the trial-data benches summarized in the references section.

Picking one GLP-1-class molecule over another is rarely a pure efficacy question — every molecule in this category clears the threshold for clinically meaningful weight loss. The differentiators are mechanism breadth, tolerance profile, cardiovascular evidence, route of administration, and access.

Start with Semaglutide when the patient has established atherosclerotic cardiovascular disease (the SELECT trial supports a hard-outcome benefit no other GLP-1 has yet matched), when prior GIP exposure caused intolerance, or when the lower price ceiling (post-compounding-cliff) drives access decisions.

Choose Tirzepatide when the priority is maximum percent body weight reduction without waiting for retatrutide approval, when obstructive sleep apnea is a documented comorbidity (Zepbound carries the specific OSA indication), or when SURMOUNT-5 head-to-head efficacy data is decisive for the patient. The Semaglutide vs Tirzepatide comparison walks the differential in clinical detail.

Wait for Retatrutide when the patient has the metabolic flexibility and time horizon to delay treatment 12–18 months for what current TRIUMPH-1 data suggests may be the highest-efficacy single-molecule option. The glucagon-receptor agonism may also reduce the metabolic-adaptation tax of pure GLP-1 monotherapy. See the Retatrutide vs Tirzepatide comparison.

Prefer Orforglipron or oral Semaglutide when needle aversion is a real treatment barrier and the patient accepts the bioavailability trade-off (oral semaglutide) or wants to wait for the non-peptide oral option (orforglipron, pending FDA decision). The oral vs injectable semaglutide comparison details the efficacy gap.

Consider CagriSema when it reaches the market — the amylin component adds a satiety-on-different-timescale mechanism that may help users who plateau on pure GLP-1 monotherapy. This decision is also driven by insurer formulary status.

In all cases the choice should be made with a prescribing clinician who has access to the patient's metabolic history, cardiovascular risk profile, and insurance coverage.

Common questions readers ask

Evidence tier: 5 — editorial framing of the peptide-page entity context.

> Evidence tier: 5 — editorial FAQ framing; per-question evidence tiers vary.

How much weight loss should I realistically expect on a GLP-1?

The trial data — STEP-1 for semaglutide (14.9% at 68 weeks), SURMOUNT-4 for tirzepatide (22.5% at 88 weeks), TRIUMPH-1 for retatrutide (~24% at 48 weeks) — represents the mean response in clinical trial populations with full adherence and titration. Real-world outcomes typically run 30–50% lower because of early discontinuation, GI tolerance issues, and incomplete dose titration. A reasonable expectation for an individual patient who reaches maintenance dose and stays on therapy 12 months is 10–18% body weight reduction. Plan around that range; the trial means are useful as upper bounds, not personal targets.

Does muscle loss on GLP-1s actually matter clinically?

Mean lean-mass loss in GLP-1 trials runs 25–40% of total weight lost — roughly proportional to what fasting and caloric restriction produce. The clinical relevance depends on baseline sarcopenia risk: a healthy 35-year-old loses lean mass they will likely regain with resistance training; an 80-year-old with low baseline lean mass cannot afford to lose more. The standard mitigations are protein intake of 1.2–1.6 g/kg/day, resistance training 2–4 times per week during weight loss, and consideration of GH-axis adjuncts like Tesamorelin under physician supervision. Discuss with a clinician before starting.

What happens when I stop taking it?

STEP-4 data: about two-thirds of lost weight is regained within 12 months of discontinuation. The 2026 framing has shifted toward GLP-1 therapy as a chronic-disease management tool rather than a discrete weight-loss intervention — analogous to antihypertensives. Tapering protocols (decreasing dose every 4–6 weeks rather than abrupt stop) may reduce rebound but do not eliminate it. Patients planning discontinuation should align lifestyle, behavioral, and possible adjunct-therapy plans well in advance with a clinician.

Is compounded semaglutide the same as Wegovy?

The active molecule is the same; the regulatory pathway, manufacturing quality assurance, and labeling are different. 503A compounding pharmacies make patient-specific preparations; 503B outsourcing facilities make larger batches under tighter quality standards. The May 4, 2026 FDA proposal would remove semaglutide and tirzepatide from the 503B bulks list — meaning 503B-scale compounding would end, while patient-specific 503A compounding under documented medical necessity continues. The full operational map is in the compounding cliff article.

Will insurance cover this?

Coverage for obesity (without diabetes) remains uneven in 2026 despite SELECT data. Most commercial plans require BMI thresholds, documented prior weight-loss attempts, and step therapy through cheaper agents before approving branded GLP-1. Medicare Part D does not cover obesity drugs at all under current statute, though the IRA and standalone bills may change that. Discuss with both your clinician and your insurer before assuming access; the answer varies by plan, state, and indication.

What we will be tracking

Evidence tier: 5 — editorial framing of the peptide-page entity context.

> Evidence tier: 5 — editorial maintenance commitment; no clinical evidence claim made.

The trial-readout calendar drives this pillar's update cadence. Active items: the Retatrutide TRIUMPH-3 cardiovascular outcomes program (expected interim H2 2026), Eli Lilly's filing of retatrutide with the FDA (anticipated H2 2026, approval window 2027–2028), the Orforglipron PDUFA decision (timing not yet announced post-ATTAIN-1), and the CagriSema REDEFINE-2 readout plus FDA PDUFA decision (late 2026). On the regulatory side we are tracking the public-comment period close on the 503B bulks-list proposal (August 3, 2026), the PCAC July 23 meeting that evaluates several peptide-class molecules in this and adjacent pillars, and any Medicare Part D obesity-coverage legislation that would expand access materially. On the access side we are watching the consolidation of 503A compounding networks, the post-503B patient migration patterns, and the emergence of any insurance-direct pathways for branded GLP-1s. Reader-visible updates will land within 72 hours of each event. The full event tracker lives on the 503B compounding cornerstone and the regulatory event index.

References

• Wilding J.P.H. et al. 2021. STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med.
• Lincoff A.M. et al. 2023. SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med.
• Jastreboff A.M. et al. 2022. SURMOUNT-1: Tirzepatide Once Weekly for Treatment of Obesity. N Engl J Med.
• Aronne L.J. et al. 2025. SURMOUNT-5: Tirzepatide vs Semaglutide for Obesity. N Engl J Med.
• Jastreboff A.M. et al. 2023. TRIUMPH-1: Retatrutide Phase 2 — triple-agonist weight loss. N Engl J Med.